Heike Woehling

Learn More
INTRODUCTION This study was conducted using an integrated retrospective database to evaluate the effectiveness of Omnitrope(®) (Sandoz) on children with growth hormone deficiency (GHD), idiopathic short stature (ISS), and Turner Syndrome (TS) who switched from a non-Omnitrope recombinant human growth hormone (rhGH) preparation during routine clinical care.(More)
AIM National European growth references differ. We aimed to convert (harmonize) currently used charts into a single unified interchangeable LMS format for each European nation. METHODS Nine currently used national European growth references from Belgium (2009), France (1979), Poland (2001), Sweden (2002), Switzerland (1989), the UK (1990), Italy (2006)(More)
The authors of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following corrections. On pages 5 and 6, Table 1 will include a footnote for the prior non-Omnitrope rhGH therapy: ''These patients are not mutually exclusive, they could have been on multiple GH therapies prior to switching to Omnitrope''. On(More)
INTRODUCTION This ongoing, prospective, open-label, non-comparative, multicenter phase IV study is evaluating the safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz GmbH) in short children born small for gestational age (SGA). Here we report data from patients who have completed 2 years' treatment. METHODS Eligibility(More)
  • 1